TACGENE was created in 2011 within U1154–UMR7196, to facilitate the access of academic laboratories to genome editing techniques.

logo tacgene
Credits
@tacgene

 

People Involved

Name   Expertise  
Carine GIOVANNANGELI Scientific Coordinator Strategy and Design
Jean-Paul CONCORDET Scientific and Technical Coordinator Strategy and Design
Anne DE CIAN Technical Coordinator ARN/Protein and in vitro activities  
Alice BRION Engineer Cellular and Molecular Biology
Khadija LAMRIBET Engineer Cellular and Molecular Biology
Marie AS Engineer Biochemistry

Contact: tacgene@mnhn.fr

Presentation

TACGENE was created in 2011 within the U1154-UMR7196, to facilitate access of academic laboratories to genome editing techniques and has enjoyed an IBiSA label since 2016.

Supported under the National Project "Investissement d'Avenir" - National Infrastructures in Biology Health, we have developed a strong expertise in the design, production and use of TALEN (transcriptional Activated Effector like Nucleases) and CRISPR (clustered interspaced short palindromic Regularly repeat) / Cas.9 technologies. We use them in cell culture in our research projects and in collaboration in many model organisms, particularly rats, mice and zebrafish thanks to the Celphedia  Network.

 

The activities of research and development we carry out in GE2R team to improve these technologies, in parallel to TACGENE service activities enable us to offer advanced solutions and expertise on the various issues of genome editing (knock-out, knock-in ...) currently available.

Strategies of genome editing proposed by TACGENE
Credits
©C.Giovannangeli

Expertise and proposed Collaborative Services

  • Design of a genome editing strategy according to the project
  • Design and selection of sgRNAs and pegRNAs
  • Usage advice and genotyping assistance
  • Provision of protocols upon request
  • Production of Cas9 and variants (mRNA and recombinant proteins)
  • Transcription of sgRNAs/pegRNAs and quality control
  • Production of donor DNA
  • In vitro activity tests of purified sgRNA/Cas9 complexes
  • Transfections and activity tests in cells
  • Cellular cloning of edited cell lines

Main Collaborations

  • Ignacio Anegon, TRIP/Inserm, Nantes (Rat Genome Editing)
  • Filippo Del Bene, Institut de la Vision/Inserm, Paris (Zebrafish Genome Editing)
  • Pierre Affaticati, TEFOR CoreFacility/CNRS, Gif-sur-Yvette (Zebrafish Genome Editing)
  • Geneviève Tavernier, Anexplo/Inserm-CNRS, Toulouse (Mouse Genome Editing)
  • Suzy Markossian, IGFL-ENS Lyon (Mouse Genome Editing)

Examples of Recent Publications involving TACGENE activities

Gaillard AL, Mohamad T, Quan FB, de Cian A, Mosimann C, Tostivint H, Pézeron G. Urp1 and Urp2 act redundantly to maintain spine shape in zebrafish larvae. Dev Biol. 2023 Apr;496:36-51. doi: 10.1016/j.ydbio.2023.01.010.

Mangeol P, Massey-Harroche D, Richard F, Concordet JP, Lenne PF, Le Bivic A. Super-resolution imaging uncovers the nanoscopic segregation of polarity proteins in epithelia. Elife. 2022 Nov 7;11:e62087. doi: 10.7554/eLife.62087.

Dos Santos M, Backer S, Auradé F, Wong MM, Wurmser M, Pierre R, Langa F, Do Cruzeiro M, Schmitt A, Concordet JP, Sotiropoulos A, Jeffrey Dilworth F, Noordermeer D, Relaix F, Sakakibara I, Maire P. A fast Myosin super enhancer dictates muscle fiber phenotype through competitive interactions with Myosin genes. Nat Commun. 2022 Feb 24;13(1):1039. doi: 10.1038/s41467-022-28666-1. PMID: 35210422; PMCID: PMC8873246.

Recazens E, Tavernier G, Dufau J, Bergoglio C, Benhamed F, Cassant-Sourdy S, Marques MA, Caspar-Bauguil S, Brion A, Monbrun L, Dentin R, Ferrier C, Leroux M, Denechaud PD, Moro C, Concordet JP, Postic C, Mouisel E, Langin D. ChREBPβ is dispensable for the control of glucose homeostasis and energy balance. JCI Insight. 2022 Feb 22;7(4):e153431. doi: 10.1172/jci.insight.153431.

Mérien A, Tahraoui-Bories J, Cailleret M, Dupont JB, Leteur C, Polentes J, Carteron A, Polvèche H, Concordet JP, Pinset C, Jarrige M, Furling D, Martinat C. CRISPR gene editing in pluripotent stem cells reveals the function of MBNL proteins during human in vitro myogenesis. Hum Mol Genet. 2021 Dec 17;31(1):41-56. doi: 10.1093/hmg/ddab218.

Joubert R, Mariot V, Charpentier M, Concordet JP, Dumonceaux J. Gene Editing Targeting the DUX4 Polyadenylation Signal: A Therapy for FSHD? J Pers Med. 2020 Dec 23;11(1):7. doi: 10.3390/jpm11010007. PMID: 33374516; PMCID: PMC7822190.

Pavani G, Laurent M, Fabiano A, Cantelli E, Sakkal A, Corre G, Lenting PJ, Concordet JP, Toueille M, Miccio A, Amendola M. Ex vivo editing of human hematopoietic stem cells for erythroid expression of therapeutic proteins. Nat Commun. 2020 Jul 29;11(1):3778. doi: 10.1038/s41467-020-17552-3. Erratum in: Nat Commun. 2020 Aug 13;11(1):4146. PMID: 32728076; PMCID: PMC7391635.

logos
logos Inserm Tefor Celphedia
Credits
©Inserm_Tefor_Celphedia
Published on: 14/06/2021 17:27 - Updated on: 05/12/2023 21:05